Clinical trials: Metastatic Colorectal Cancer (MCRC)
Colorectal Cancer
Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)
This observational study will assess the treatment duration, progression-free survival, reason for stopping treatment and patient and tumor characteristics of bevacizumab [Avastin] treatment in patients with metastatic colorectal…
- Trial name
- NCT01089413
- Testing
- bevacizumab [Avastin]
- Where
- 19 sites in Belgium
- Volunteers
- 201 people
- Sponsor
- Hoffmann-La Roche
Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
- Conditions
- Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)
- Trial name
- NCT07566897
- Testing
- L19IL2, Ruxolitinib
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.
Metastatic Colorectal Cancer
A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece
Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population.
- Trial name
- RETRO-TAS (NCT04965870)
- Testing
- Trifluridine/Tipiracil
- Where
- 8 sites in Greece
- Volunteers
- 200 people
- Sponsor
- Hellenic Study Group of Psychoneuroimmunology in Cancer
Metastatic Colorectal Carcinoma (mCRC)
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
The standard second-line treatment for metastatic colorectal cancer (mCRC) involves chemotherapy (FOLFOX or FOLFIRI) combined with an antiangiogenic agent, such as bevacizumab or aflibercept.
- Trial name
- NCT07150403
- Testing
- Oxaliplatin intravenous, 5 FU bolus, Folinic acid
- Where
- 45 sites in France
- Volunteers
- 74 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Metastatic Colorectal Cancer (MCRC)
Phase I/II Combination With Irinotecan- Erbitux
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median…
- Trial name
- NCT00594984
- Testing
- Cetuximab, Irinotecan, Brivanib
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)
The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. This expanded access program provides adults with refractory metastatic colorectal cancer (mCRC) and who cannot neither…
- Trial name
- NCT06195514
- Testing
- TAK-113
- Sponsor
- Takeda
Colorectal Neoplasm
Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
The purpose of the study is to investigate the safety and effectiveness of Stivarga in patients with metastatic colorectal carcinoma in routine use in Germany.
- Trial name
- RECORA (NCT01959269)
- Testing
- Regorafenib (Stivarga, BAY 73-4506)
- Where
- Germany
- Volunteers
- 483 people
- Sponsor
- Bayer
Colorectal Cancer
A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib…
- Trial name
- NCT07035886
- Testing
- No intervention
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Takeda
Colorectal Neoplasms Malignant
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
This is a multicenter, randomized, controlled, phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab and irinotecan（group A） compared to third-line regimens selected by researchers（group B） in…
- Trial name
- NCT05278351
- Testing
- Tislelizumab Combined With Cetuximab and Irinotecan, Third-line regimens
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Colorectal Cancer
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
Immune checkpoint inhibitors have a poor effect on MSS colorectal cancer. Studies have shown that SBRT, chemotherapy and anti-vascular therapy can enhance the anti-tumor effect of PD-1 antibody.
- Trial name
- NCT05438108
- Testing
- SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huazhong University of Science and Technology
Pretreated Metastatic Colorectal Cancer
Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy
0116-ASG REMETY is a multicenter, open-label, non-randomized, dose-escalation Phase I study evaluating the safety and anti-tumor activity of TAS-102 administered in combination with Regorafenib in patients with metastatic…
- Trial name
- REMETY (NCT03305913)
- Testing
- TAS 102, Regorafenib
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- AIO-Studien-gGmbH
Colorectal Cancer Metastatic
A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
Primary Objective: To evaluate the improvement in progression-free survival (PFS) of aflibercept versus placebo in participants with metastatic colorectal cancer treated with FOLFIRI as second-line treatment for metastatic…
- Trial name
- AFLAME (NCT01661270)
- Testing
- Aflibercept
- Where
- 37 sites in China, Hong Kong and 3 more
- Volunteers
- 332 people
- Sponsor
- Sanofi
Colorectal Cancer Metastatic, Fecal Microbiota Transplantation
Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer
This research protocol outlines an exploratory study on the combination of early-life fecal microbiota transplantation (yFMT) with immunotherapy and chemotherapy in patients with microsatellite stable metastatic colorectal cancer…
- Trial name
- NCT07486492
- Testing
- yFMT
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
CRC
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
The study consists of the two parts, phase IIa and phase IIb.
- Trial name
- mCRC (NCT05233332)
- Testing
- HL-085, Vemurafenib
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary Objective: To evaluate the safety of aflibercept in participants with mCRC treated with irinotecan/5-Fluorouracil (5-FU) combination (FOLFIRI) after failure of an oxaliplatin-based regimen (participants similar to those…
- Trial name
- AFEQT (NCT01670721)
- Testing
- AFLIBERCEPT, Irinotecan, Fluorouracil
- Where
- France
- Volunteers
- 175 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line…
- Trial name
- daNIS-3 (NCT04952753)
- Testing
- NIS793, Bevacizumab, Modified FOLFOX6
- Where
- 55 sites in United States, Australia and 15 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Colorectal Cancer
EORTC-endorsed, Prospective European Multicenter Imaging Survey and Protocol
A prospective, multicenter imaging Delphi survey among European radiological societies for mCRC imaging standardization.
- Trial name
- NCT04656782
- Testing
- Imaging survey, Facilitation
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Metastatic Colorectal Cancer, Drug Therapy
Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC
To evaluate the efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.
- Trial name
- NCT06485713
- Testing
- trifluridine/tipiracil combined with fufuquitinib, fufuquitinib, Trifluridine/tipiracil
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Metastatic Colorectal Cancer (mCRC)
DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen's Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical…
- Trial name
- NCT06645236
- Testing
- therascreen® KRAS RGQ PCR Kit
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Metastatic Colorectal Cancer
An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States
This is an observational study in which data already collected from patients with metastatic colorectal cancer will be studied. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part…
- Trial name
- COLONGER (NCT06029010)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- United States
- Volunteers
- 2,326 people
- Sponsor
- Bayer